[Federal Register: August 10, 2004 (Volume 69, Number 153)]
[Notices]               
[Page 48522]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr10au04-119]                         

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Importer of Controlled Substances; Notice of Application

    Pursuant to 21 U.S.C. 958(I), the Attorney General shall, prior to 
issuing a registration under this section to a bulk manufacturer of a 
controlled substance in Schedule I or II and prior to issuing a 
registration under 21 U.S.C. 952(a)(2)(B) authorizing the importation 
of such a substance, provide manufacturers holding registrations for 
the bulk manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with 21 CFR 1301.34(a), this is notice 
that on May 8, 2004, Hospira, Inc., 1776 North Centennial Drive, 
McPherson, Kansas 67460-1247, made application to the Drug Enforcement 
Administration (DEA) for registration as an importer of Remifentanil 
(9739), a basic class of controlled substance listed in Schedule II.
    The company plans to import the basic class of controlled substance 
for use in dosage unit manufacturing.
    Any manufacturer who is presently, or is applying to be, registered 
with DEA to manufacture such basic class of controlled substance may 
file comments or objections to the issuance of the proposed 
registration and may, at the same time, file a written request for a 
hearing on such application pursuant to 21 CFR 1301.43 and in such form 
as prescribed by 21 CFR 1316.47.
    Any such comments or objection or requests for hearing may be 
addressed, in quintuplicate, to the Deputy Assistant Administrator, 
Office of Diversion Control, Drug Enforcement Administration, United 
States Department of Justice, Washington, DC 20537, Attention: DEA 
Federal Register Representative (CCD) and must be filed no later than 
September 9, 2004.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e) and (f). As noted in a previous notice published in the Federal 
Register on September 23, 1975, (40 FR 43745-46), all applicants for 
registration to import a basic class of any controlled substances in 
Schedule I or II are and will continue to be required to demonstrate to 
the Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration, that the requirements for such registration 
pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), 
(c), (d), (e) and (f) are satisfied.

    Dated: July 28, 2004.
Joseph T. Rannazzisi,
Deputy Director, Office of Diversion Control, Drug Enforcement 
Administration.
[FR Doc. 04-18176 Filed 8-9-04; 8:45 am]

BILLING CODE 4410-09-M